Brief: Akero Therapeutics Reports 36-Week Analysis Of 96-Week Phase 2B Symmetry Study

Akero Therapeutics

10/10/2023 12:58

Oct 10 (Reuters) - Akero Therapeutics Inc  AKRO.O :
    * AKERO THERAPEUTICS REPORTS ENCOURAGING 36-WEEK ANALYSIS OF
96-WEEK PHASE 2B SYMMETRY STUDY, WITH A TREND ON FIBROSIS
IMPROVEMENT AND STATISTICALLY SIGNIFICANT RESULTS FOR NASH
RESOLUTION, MARKERS OF LIVER INJURY AND FIBROSIS, INSULIN
SENSITIZATION AND LIPOPROTEINS
    * AKERO THERAPEUTICS - 4% PATIENTS IN EACH EFX DOSE GROUP
EXPERIENCED THREE- OR TWO-STAGE REVERSAL OF FIBROSIS WITH NO
WORSENING OF NASH, VERSUS 0% PLACEBO
    * AKERO THERAPEUTICS INC - EFX WAS REPORTED TO BE GENERALLY
WELL-TOLERATED
    * AKERO THERAPEUTICS INC - ACROSS ALL THREE GROUPS, THERE
WAS ONE
DEATH IN A PLACEBO PATIENT WHO HAD PNEUMONIA
    * AKERO THERAPEUTICS INC - TWENTY-ONE SERIOUS ADVERSE EVENTS
WERE
REPORTED, WHICH WERE GENERALLY BALANCED ACROSS DOSE GROUPS
    * AKERO THERAPEUTICS INC -  NONE OF SERIOUS ADVERSE EVENTS
WERE
REPORTED AS TREATMENT-RELATED BY CLINICAL INVESTIGATORS

Source text for Eikon:  ID:nGNX5FZRkK 
Further company coverage:  AKRO.O 

 ((Reuters.Briefs@thomsonreuters.com;))